Robocath in a few words

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer, thanks to reliable technologies, while complementing manual interventions.
R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. It is designed to operate with precision and perform specific movements creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.


Company foundation
First in vivo tests
ISO 13485 certification granted
Industrial prototype
Safety-Efficacy study
R-One pre-launch

Robocath in the world

19 Rue Marie Curie, Rouen, France
50 Milk Street, Boston, Massachusetts, États-Unis


A doctor of medicine and a graduate of the 'Healthcare Industry Strategy and Management' program at ESSEC Business School, Philippe Bencteux has over twenty years of experience in vascular imaging. A trained neuro-radiologist, he founded Robocath in 2009 on the basis of the promising preliminary research carried out in collaboration with two engineering schools. He has since contributed his expertise in the medical sector to the company and is actively involved in the conception of new robotics solutions.
Holding a master’s degree in Business, Lucien Goffart started his career in 1999 at Johnson & Johnson Inc. Then, he joined Abbott before holding different positions at Volcano company between 2004 and 2011. From 2012 to 2014, he held different executive positions at Stentys and Mitralgin. Last four years, he served Boston Scientific as Business Unit Manager France. In the meanwhile, he was Board member of several companies from the Medtech industry such as Opsens Medical. Since 2019, he is Board member of Electroducer and was appointed CEO of Robocath in September.
Bruno Fournier is a trained engineer (Supélec) and Doctor of Science (Université Paris VI), with strong R&D experience in the healthcare sector. He led the development of products with high added value in several fields (ultrasound, bone density measurement, respiratory support, etc.). Passionate about new medical technologies, he joined Robocath in 2012 after management roles with the Air Liquide Groupe and his time as Director of R&D at one of Getinge Group subsidiary from 2006 to 2012.
Graduated from HEC and holding a Phd in accountancy, Dominique DESTRIEZ started his career in international audit and management accounting within large companies afterwards. He then joined Nocibé, a french comestic group, as financial director and played an active role in the company’s growth from 1999 to 2004. For over 15 years, Dominique supports investment funds and their participations to achieve financial structuring, M&A, funds raising, international development and stock exchange listing.

Strategic Committee

M Capital Partners is an independent and entrepreneurial French investment and financing company. It took a stake in Robocath in 2017.
Newly created by the CEA Investissement seasoned funds management team, CEA and Amundi, Supernova Invest is specialized in deep-tech venture capital in life sciences, energy and industry (electronics, advanced materials, instruments…).
Normandie Participations, an equity financing tool backed by AD Normandie, is a regional financing structure for equity participations in companies based in Normandy. The fund took a stake in Robocath in 2017.
An historic investor in Robocath (since 2013), NCI is a major player in capital investment in Normandy.
An historic investor in Robocath (since 2013), GO CAPITAL is an investment fund management company that favors companies with high growth potential in the fields of healthcare, technology (hardware and software), digital and innovative services.

Medical Advisory Board

Professor of medicine and former chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI (Transcatheter Aortic Valve Implantation) procedure, a breakthrough, less invasive interventional treatment for structural heart diseases. Since its creation, the device has been implanted in thousands of patients around the world. He is the author of more than 600 publications and has received several major international medical and scientific awards.
• co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.
Head of the Villa Maria hospital cardiovascular department in Bologna (Italy) for the last 25 years, published many interventional cardiology and peripheral vascular papers. From 2011 to 2013, he was president of the Italian society of interventional cardiology. He has for many years been an active member of the PCR board and received several awards in recognition of his achievements.
professor of medicine and director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation, both in New York. Regularly engaged in clinical research and professional education, he has led and published more than 2,000 manuscripts and abstracts and has received several major awards for his work. He is director of the TCT Congress (Transcatheter Cardiovascular Therapeutics), one of the largest interventional cardiology gatherings in the world.
Pr. Haude has been head physician of the Medical Clinic I at the Clinic Neuss for 13 years and is thus also in charge of cardiology and of their cardiac catheter labs. In addition, Professor Haude has been involved in interventional cardiology for 31 years and has been past chairman of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology , PCR and ESC board member and EAPCI president from 2016 to 2018. He currently is an EAPCI board member, Pr. Haude has published more than 300 scientific articles.
Dr. Lorgat is an interventional cardiologist at Christiaan Barnard Memorial Hospital since 1998. As one of the first users of a robotic system for electrophysiology, Dr. Lorgat has performed more than 1,600 procedures with this robotic assistance over a period of 6 years and is an active research contributor in this field.


Rated as fourth Medical French Start-up
by Forbes Magazine
Winner of the TechInnov Award 2015
Nominee for "Trophée de l'Avenir" 2018
by Europe 1
Nominee for French Start-up of the year 2018
by EY